Jiangsu Lianhuan Pharmaceutical (600513.SH): Active Pharmaceutical Ingredient Levonorgestrel Passes WHO Prequalification On-Site Inspection

Stock News11-10

Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SH) announced that it has recently received notification from the World Health Organization (WHO). The WHO prequalification team has concluded the on-site inspection of the company's active pharmaceutical ingredient (API) product Levonorgestrel (APIMF484, WHOAPI-484), confirming compliance with WHO Good Manufacturing Practice (GMP) standards.

The successful completion of this inspection demonstrates that the company's relevant production line meets GMP requirements, ensuring continued stable product quality and sustained production capacity to fulfill market demand for related pharmaceutical products. However, the passing of this WHO prequalification inspection is not expected to have a significant impact on the company's near-term financial performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177609540?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177609540","market":"hk","top_or_hot":-1,"title":"Jiangsu Lianhuan Pharmaceutical (600513.SH): Active Pharmaceutical Ingredient Levonorgestrel Passes WHO Prequalification On-Site Inspection","media":"Stock News","content":"<p>Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SH) announced that it has recently received notification from the World Health Organization (WHO). The WHO prequalification team has concluded the on-site inspection of the company's active pharmaceutical ingredient (API) product Levonorgestrel (APIMF484, WHOAPI-484), confirming compliance with WHO Good Manufacturing Practice (GMP) standards.</p>\n<p>The successful completion of this inspection demonstrates that the company's relevant production line meets GMP requirements, ensuring continued stable product quality and sustained production capacity to fulfill market demand for related pharmaceutical products. However, the passing of this WHO prequalification inspection is not expected to have a significant impact on the company's near-term financial performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Lianhuan Pharmaceutical (600513.SH): Active Pharmaceutical Ingredient Levonorgestrel Passes WHO Prequalification On-Site Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Lianhuan Pharmaceutical (600513.SH): Active Pharmaceutical Ingredient Levonorgestrel Passes WHO Prequalification On-Site Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-10 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SH) announced that it has recently received notification from the World Health Organization (WHO). The WHO prequalification team has concluded the on-site inspection of the company's active pharmaceutical ingredient (API) product Levonorgestrel (APIMF484, WHOAPI-484), confirming compliance with WHO Good Manufacturing Practice (GMP) standards.</p>\n<p>The successful completion of this inspection demonstrates that the company's relevant production line meets GMP requirements, ensuring continued stable product quality and sustained production capacity to fulfill market demand for related pharmaceutical products. However, the passing of this WHO prequalification inspection is not expected to have a significant impact on the company's near-term financial performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1177609540","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177609540","pubTimestamp":1762765221,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SH) announced that it has recently received notification from the World Health Organization (WHO). The WHO prequalification team has concluded the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600513":"联环药业","BK0239":"医药制造"},"translate_title":"江苏联环药业（600513.SH）：活性药物成分左炔诺孕酮通过WHO资格预审现场检查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600513":1},"content_text":"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SH) announced that it has recently received notification from the World Health Organization (WHO). The WHO prequalification team has concluded the on-site inspection of the company's active pharmaceutical ingredient (API) product Levonorgestrel (APIMF484, WHOAPI-484), confirming compliance with WHO Good Manufacturing Practice (GMP) standards.\nThe successful completion of this inspection demonstrates that the company's relevant production line meets GMP requirements, ensuring continued stable product quality and sustained production capacity to fulfill market demand for related pharmaceutical products. However, the passing of this WHO prequalification inspection is not expected to have a significant impact on the company's near-term financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177609540","isCrawlerRequest":true}